Q2 Earnings Forecast for SPTX Issued By HC Wainwright

Seaport Therapeutics, Inc. (NASDAQ:SPTX) – Research analysts at HC Wainwright issued their Q2 2026 earnings per share estimates for Seaport Therapeutics in a note issued to investors on Wednesday, July 15th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of ($0.96) for the quarter. HC Wainwright currently has a “Buy” rating and a $50.00 price target on the stock. HC Wainwright also issued estimates for Seaport Therapeutics’ Q3 2026 earnings at ($0.54) EPS, Q4 2026 earnings at ($0.58) EPS, FY2026 earnings at ($3.25) EPS, Q1 2027 earnings at ($0.61) EPS, Q2 2027 earnings at ($0.64) EPS, Q3 2027 earnings at ($0.66) EPS, Q4 2027 earnings at ($0.69) EPS and FY2027 earnings at ($2.60) EPS.

Seaport Therapeutics (NASDAQ:SPTX) last announced its earnings results on Monday, June 8th. The company reported ($10.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($10.64) by $0.30.

A number of other analysts have also commented on the stock. Stifel Nicolaus began coverage on shares of Seaport Therapeutics in a research report on Tuesday, May 26th. They issued a “buy” rating and a $30.00 price objective on the stock. Zacks Research raised shares of Seaport Therapeutics to a “hold” rating in a research report on Wednesday, May 27th. Wolfe Research initiated coverage on shares of Seaport Therapeutics in a research note on Tuesday, July 7th. They issued a “hold” rating on the stock. Seaport Research Partners set a $50.00 price target on shares of Seaport Therapeutics in a research note on Wednesday. Finally, Leerink Partners assumed coverage on shares of Seaport Therapeutics in a research report on Tuesday, May 26th. They set an “outperform” rating and a $35.00 price target on the stock. Five analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Seaport Therapeutics has an average rating of “Hold” and a consensus target price of $38.40.

Seaport Therapeutics Stock Performance

NASDAQ:SPTX opened at $20.85 on Monday. The firm has a market cap of $1.12 billion and a P/E ratio of -2.02. Seaport Therapeutics has a twelve month low of $14.85 and a twelve month high of $23.00. The business’s 50 day moving average price is $18.43.

Insider Buying and Selling

In related news, Director Robert J. Hombach purchased 13,000 shares of the firm’s stock in a transaction on Monday, June 22nd. The stock was purchased at an average cost of $18.14 per share, for a total transaction of $235,820.00. Following the completion of the purchase, the director directly owned 13,000 shares in the company, valued at $235,820. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Arch Venture Partners Xii, Llc acquired 1,100,000 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was bought at an average cost of $18.00 per share, with a total value of $19,800,000.00. Following the acquisition, the insider owned 6,294,951 shares in the company, valued at $113,309,118. The trade was a 21.17% increase in their position. The disclosure for this purchase is available in the SEC filing.

More Seaport Therapeutics News

Here are the key news stories impacting Seaport Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Seaport Therapeutics and assigned a $50 price objective, implying substantial upside from current levels.
• Neutral Sentiment: The firm issued detailed earnings estimates for upcoming quarters and fiscal years, including expected losses of ($0.96) in Q2 2026, ($0.54) in Q3 2026, ($0.58) in Q4 2026, and ($3.25) for FY2026. Article Title
• Neutral Sentiment: HC Wainwright also forecast continued losses in 2027, with EPS estimates of ($0.61) for Q1, ($0.64) for Q2, ($0.66) for Q3, ($0.69) for Q4, and ($2.60) for FY2027.